CN102755628A - Antifungal pharmaceutical composition - Google Patents
Antifungal pharmaceutical composition Download PDFInfo
- Publication number
- CN102755628A CN102755628A CN201210245954XA CN201210245954A CN102755628A CN 102755628 A CN102755628 A CN 102755628A CN 201210245954X A CN201210245954X A CN 201210245954XA CN 201210245954 A CN201210245954 A CN 201210245954A CN 102755628 A CN102755628 A CN 102755628A
- Authority
- CN
- China
- Prior art keywords
- posaconazole
- pharmaceutical composition
- following
- reduced
- antifungal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 21
- 229940121375 antifungal agent Drugs 0.000 title claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 9
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 claims abstract description 25
- 229960001589 posaconazole Drugs 0.000 claims abstract description 25
- 108010009858 Echinomycin Proteins 0.000 claims abstract description 18
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002207 metabolite Substances 0.000 claims abstract description 12
- 229940002612 prodrug Drugs 0.000 claims abstract description 12
- 239000000651 prodrug Substances 0.000 claims abstract description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- 241000233866 Fungi Species 0.000 claims abstract description 8
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims abstract description 8
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical compound CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 claims abstract 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 2
- 229940088710 antibiotic agent Drugs 0.000 claims abstract 2
- -1 triazole compounds Chemical class 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 27
- 206010017533 Fungal infection Diseases 0.000 claims description 13
- 208000031888 Mycoses Diseases 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 8
- 241000222122 Candida albicans Species 0.000 claims description 4
- 229940095731 candida albicans Drugs 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 3
- 241000223218 Fusarium Species 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 241000228212 Aspergillus Species 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 208000037026 Invasive Fungal Infections Diseases 0.000 abstract description 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 238000012404 In vitro experiment Methods 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- AUJXLBOHYWTPFV-VITLIGDRSA-N n-[(1r,4s,7r,11s,14r,17s,20r,24s)-2,4,12,15,17,25-hexamethyl-29-methylsulfanyl-3,6,10,13,16,19,23,26-octaoxo-11,24-di(propan-2-yl)-7-(quinoxaline-2-carbonylamino)-9,22-dioxa-28-thia-2,5,12,15,18,25-hexazabicyclo[12.12.3]nonacosan-20-yl]quinoxaline-2-carbo Chemical compound C([C@H](C(=O)N[C@@H](C)C(=O)N1C)NC(=O)C=2N=C3C=CC=CC3=NC=2)OC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]2N(C)C(=O)[C@H](C)NC(=O)[C@H](NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]1CSC2SC AUJXLBOHYWTPFV-VITLIGDRSA-N 0.000 description 14
- 241001597008 Nomeidae Species 0.000 description 6
- 241000675278 Candida albicans SC5314 Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- FIVPIPIDMRVLAY-RBJBARPLSA-N gliotoxin Chemical compound C1C2=CC=C[C@H](O)[C@H]2N2[C@]1(SS1)C(=O)N(C)[C@@]1(CO)C2=O FIVPIPIDMRVLAY-RBJBARPLSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抗真菌药物组合物。该药物组合物由A和B组成；其中，所述A选自下述至少一种：喹喔啉类抗生素及其类似物、衍生物、前药、代谢物和药物活性盐；所述B选自下述至少一种：三唑类化合物及其类似物、衍生物、前药、代谢物和药物活性盐。体外抗菌试验证明，将泊沙康唑和棘霉素联合应用，表现出很强的协同活性。使双方的用药剂量均降低32-64倍，体外实验中仍能保证受试真菌被100％清除。这样的组合物将提供联合治疗，对于具有难治性，侵入性的真菌感染是有效的。并且可以因此降低泊沙康唑的用药剂量，减轻患者的经济负担，减轻泊沙康唑的毒性反应，有效降低真菌耐药性的发展。The invention discloses an antifungal pharmaceutical composition. The pharmaceutical composition is composed of A and B; wherein, said A is selected from at least one of the following: quinoxaline antibiotics and their analogs, derivatives, prodrugs, metabolites and pharmaceutically active salts; said B is selected from At least one of the following: triazole compounds and their analogs, derivatives, prodrugs, metabolites and pharmaceutically active salts. Antibacterial tests in vitro proved that the combined application of posaconazole and echinomycin showed strong synergistic activity. The dosages of both parties are reduced by 32-64 times, and the tested fungus can still be guaranteed to be 100% eliminated in the in vitro experiment. Such compositions would provide combination therapy effective for refractory, invasive fungal infections. In addition, the dose of posaconazole can be reduced, the economic burden of patients can be reduced, the toxicity of posaconazole can be reduced, and the development of fungal drug resistance can be effectively reduced.
Description
Technical field
The present invention relates to a kind of antifungal medicament compositions.
Background technology
Fungal infection, the especially sickness rate of hypoimmunity patient opportunistic fungal infection constantly rise treatment of fungal infections are faced with formidable challenges.Though there are some fungi-medicines to come out one after another, treatment has brought new favourable turn to fungal infection, and the simultaneously relevant drug-fast report of Drug therapy also increases gradually.Therefore need the new antifungal therapy method of development.
Posaconazole generally is used for intractable and invasive infections with fungi or other medicines drug resistance cause fungal infection.This kind infection generally occurs on one's body the patient of immunity infringement, for example organ transplantation or carry out the patient of chemotherapy.Compare with itraconazole with the control drug fluconazol of anti-fungal infection, posaconazole more can effectively prevent the aggressive aspergillin infection and can reduce the relevant mortality rate of invasive infections with fungi.But posaconazole costs an arm and a leg, and often follows some serious adverse reactions such as hyperbilirubinemia in the therapeutic process, and liver enzyme raises, symptoms such as hepatocellular damage and nausea and vomiting.
Summary of the invention
The purpose of this invention is to provide a kind of antifungal medicine composition with synergistic function.
Antifungal medicine composition provided by the present invention is made up of A and B; Wherein, Said A is selected from following at least a: quinoxaline antibiotic and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt, said B is selected from following at least a: triazole class compounds and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
In some embodiments, said A is selected from following any one material: Quinomycin A. and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
In some embodiments, said B is selected from following any one material: posaconazole and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt.
In the preferred embodiment, said A is a Quinomycin A., and said B is a posaconazole, and both mass ratioes are (12.5-1600): 1, and preferred mass is than being (200-1600): 1.
Antibiotic of quinoxaline described in the present invention and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt can obtain through microbial fermentation, chemical improvement, chemosynthesis or commercial sources.
Triazole class compounds described in the present invention and analog thereof, derivant, prodrug, metabolite and pharmaceutically active salt can obtain through chemosynthesis or commercial sources.
Another object of the present invention provides the application of above-mentioned antifungal medicine composition.
To be it be used for treating the application of the medicine of fungal infection in preparation in application provided by the present invention.
In some embodiments, the fungus that is infected can be selected from but be not limited to by aspergillosis, Fusarium spp., Candida albicans (being saccharomyces albicans).
The present invention also protects a kind of medicine that is used to treat fungal infection.
The medicine that the present invention protected, its active component are antifungal medicine composition of the present invention.
But the method for said medicine administered through oral, external, injection, infiltration, absorption, physics or chemistry mediation imports body such as muscle, Intradermal, subcutaneous, vein or mucosal tissue; Or by other material mixing or parcel back importing body.
When needing, in said medicine, can also add one or more pharmaceutically acceptable carriers.Said carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier and the lubricant etc. that pharmaceutical field is conventional.
The said medicine that is used to treat fungal infection can be processed various ways such as injection, tablet, powder, granule, capsule, unguentum, cream.The medicine of above-mentioned various dosage forms all can be according to the conventional method preparation of pharmaceutical field.
The in-vitro antibacterial evidence with posaconazole and Quinomycin A. Combined application, shows very strong synergistic activity.Make both sides' dosage all reduce 32-64 doubly, still can guarantee to be tried fungus in the experiment in vitro and removed by 100%.Such compositions will provide therapeutic alliance, and will be intractable for having, and invasive fungal infection is effective.And can therefore reduce the dosage of posaconazole, alleviate patient's financial burden, alleviate the toxic reaction of posaconazole, effectively reduce the chemical sproof development of fungus.
Description of drawings
Fig. 1 is the collaborative antifungal activity result (composition of medicine MIC value during 100% inhibition conk) of posaconazole and Quinomycin A.
The specific embodiment
The present invention will be described through specific embodiment below, but the present invention is not limited thereto.
Experimental technique described in the following embodiment like no specified otherwise, is conventional method; Said reagent and biomaterial like no specified otherwise, all can obtain from commercial sources.
Used Candida albicans (Candida albicans SC5314/ATCC MYA-2876) is available from the biological article collecting center (American Type Culture Collection) of Unite States Standard among the following embodiment.
The interactive antifungal activity test of embodiment 1, Quinomycin A. and posaconazole
Using chessboard method tests interactive antifungal (the Candida albicans SC5314) activity of Quinomycin A. and posaconazole.Concrete grammar is:
Candida albicans SC5314 in the RPMI1640 culture medium, 35 ℃, humidity 80%, 5%CO
2Condition under hatch.Quinomycin A. and posaconazole are dissolved in respectively among the DMSO, to concentration be 1mg/mL, stored for future use in refrigerator.In order to measure minimal inhibitory concentration (MIC), adopt doubling dilution during sample test.Specifically with reference to the M-27A of standardization committee of American National clinical laboratory (NCCLS) scheme, i.e. " yeast liquid media dilution method antifungal drug STT scheme ".Adopt 2 times of dilution methods to prepare the medicinal liquid of a series of diluted concentrations with fluid medium (RPMI1640), then with Candida albicans SC5314 cell (78 μ l ,～1 * 10
4Individual) be inoculated in 96 orifice plates, the back adds 2 μ l drug solutions.First medicine posaconazole is vertically arranged by diluted concentration on 96 orifice plates, and second medicine Quinomycin A. laterally arranged by diluted concentration.Hatch test OD value after 18 hours for 35 ℃.Compare to confirm the MIC value through OD value with blank.The MIC value defined is the lowest drug concentration that ability 100% suppresses conk here.
For confirm to work in coordination with between two medicine A and the B, addition or antagonism, we judge through inhibition concentration coefficient FICI.FICI=(A/MICA in the MIC drug regimen is independent)+(B/MICB in the MIC drug regimen is independent) is if FICI value＜0.50 then shows to have interactive activity; If the FICI value is between 0.5-4.0; Then for showing active addition, if FICI value＞4.0 then show to have antagonism between the two.
Table 1. is worked in coordination with the antifungal activity test result
The result shows that posaconazole concentration is 0.002ug/ml, and Quinomycin A. concentration is 0.025ug/ml; Posaconazole concentration is 0.001ug/ml, and Quinomycin A. concentration is 0.05ug/ml; Posaconazole concentration is 0.0005ug/ml, and Quinomycin A. concentration is 0.1ug/ml; Posaconazole concentration is 0.00025ug/ml, and Quinomycin A. concentration is 0.1ug/ml; Posaconazole concentration is 0.000125ug/ml, and all there was collaborative antifungic action in two chemical compounds when Quinomycin A. concentration was 0.2ug/ml.Wherein posaconazole concentration is 0.00025ug/ml, and when Quinomycin A. concentration was 0.1ug/ml, collaborative antifungal activity was the strongest.
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210245954 CN102755628B (en) | 2012-07-16 | 2012-07-16 | A kind of antifungal pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210245954 CN102755628B (en) | 2012-07-16 | 2012-07-16 | A kind of antifungal pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102755628A true CN102755628A (en) | 2012-10-31 |
| CN102755628B CN102755628B (en) | 2013-10-23 |
Family
ID=47050435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210245954 Expired - Fee Related CN102755628B (en) | 2012-07-16 | 2012-07-16 | A kind of antifungal pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102755628B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688306A (en) * | 2002-09-23 | 2005-10-26 | 先灵公司 | Use of posaconazole for the treatment of fungal infections |
| CN1988887A (en) * | 2004-05-28 | 2007-06-27 | 先灵公司 | Injectable pharmaceutical suspension comprising posaconazole |
| CN102391968A (en) * | 2011-11-17 | 2012-03-28 | 中国科学院微生物研究所 | Streptomyces and its application in echinomycin production |
-
2012
- 2012-07-16 CN CN 201210245954 patent/CN102755628B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1688306A (en) * | 2002-09-23 | 2005-10-26 | 先灵公司 | Use of posaconazole for the treatment of fungal infections |
| CN1988887A (en) * | 2004-05-28 | 2007-06-27 | 先灵公司 | Injectable pharmaceutical suspension comprising posaconazole |
| CN102391968A (en) * | 2011-11-17 | 2012-03-28 | 中国科学院微生物研究所 | Streptomyces and its application in echinomycin production |
Non-Patent Citations (2)
| Title |
|---|
| 陈念等: "喹喔啉类抗肿瘤抗生素研究进展", 《实用医学杂志》, vol. 22, no. 21, 30 November 2006 (2006-11-30), pages 2569 - 2570 * |
| 陈敏等: "泊沙康唑治疗侵袭性真菌病研究进展", 《中国实用内科杂志》, vol. 32, no. 2, 29 February 2012 (2012-02-29), pages 154 - 157 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102755628B (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Drug repurposing strategies in the development of potential antifungal agents | |
| JP2013535422A5 (en) | ||
| CN109475524A (en) | Compositions and methods for reducing neutropenia | |
| US11554109B2 (en) | Pemafibrate dosing regimens | |
| CN103536613B (en) | A kind of antifungal pharmaceutical composition | |
| EP3843737A1 (en) | Pde9 inhibitors for treating sickle cell disease | |
| Soysal | Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole | |
| Said et al. | Sirolimus‐itraconazole interaction in a hematopoietic stem cell transplant recipient | |
| KR101572529B1 (en) | Tetraarsenic oxide combination therapy for cancer treatment | |
| JP2020529999A (en) | Antifungal agent showing enhanced activity at acidic pH | |
| CN102755628B (en) | A kind of antifungal pharmaceutical composition | |
| RU2195937C1 (en) | Combined antituberculosis preparation (rizobutol) | |
| Mergenhagen et al. | Daptomycin use after vancomycin-induced neutropenia in a patient with left-sided endocarditis | |
| Taboada et al. | Systemic antifungal therapy | |
| CN102872059B (en) | Application of Gypensapogenin B to preparing drugs for resisting human funguses | |
| CN113456641B (en) | Application of a compound in the preparation of antifungal drugs | |
| CN113318107B (en) | Application of nitrogen-containing compound in preparation of antifungal medicine | |
| Can et al. | Invasive pulmonary aspergillosis after liver transplantation: rapid and complete response to combined and sequential antifungal therapy | |
| CN104083360B (en) | A kind of Chinese medicine composition for the preparation of anti-aspergillosis medicine | |
| CN101966190A (en) | Amlodipine and eprosartan-containing compound preparation for treating hypertension | |
| JPH0338521A (en) | Antifungal composition | |
| CN108113990A (en) | A kind of pharmaceutical composition for treating urinary tract infections | |
| Deck et al. | Pharmacological advances in the treatment of invasive candidiasis | |
| CN103463029B (en) | Application of Lycojaponicumin B in human fungus resisting medicine | |
| CN103479636B (en) | The application of Lycojaponicumin C in preparation anti-human fungi medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131023 Termination date: 20200716 |